Database Member Home
RAS Member Home
Key opinion leaders (KOL) play a significant role in a biopharmaceutical product’s development by providing clinical and scientific expertise during initial phase, influencing peers and serving as advocates and spokespersons at product launch. However, increasing regulatory restrictions have forced biopharmaceutical companies to reassess their approach to KOL management.
This video provides guidelines for effective KOL development and engagement to promote long term viability. It discusses the strategic approaches to thought leader management to be adopted by an organization as it evolves, KOL management responsibility in the organization and interpreting the impact of legislative changes on business operations.
Insights from this video will help Medical Affairs professionals in comparing their approach to Key Opinion Leader management against industry standards and identify scope for improvement.
Pharmaceutical companies continue to improve the effectiveness of their managed care interactions by employing specialized medical liaisons who can speak the "payer language... (ID POP-283)
Read More »
In pharma, regulatory and access restrictions have reshaped key interactions with thought leaders... (ID POP-267)
Key Opinion Leaders (KOLs) are recognized as one of the most effective avenues for building awareness in medical and scientific communities... (ID POP-253)
Pharmaceutical and life science companies rely heavily on key opinion leaders (KOLs) to improve their credibility in the marketplace... (ID PSM-235)
Pharmaceutical and medical device organizations seek strategic insights and guidance to successfully navigate the complexities of the changing healthcare landscape... (ID PSM-319)
As Medical Science Liaisons (MSLs) increasingly face restricted access to physicians and KOLs, it is important for biopharmaceutical and medical device companies to empower MSLs with new processes and tools that facilitate rapid and effective customer engagement... (ID POP-286)
The growing demand for scientific and medical data in the biopharmaceutical industry has pushed organizations to develop effective KOL engagement strategies for their field-based medical and field-based outcomes and pricing group... (ID POP-288)